Pharmacokinetics of Vacomycin
*Corresponding Author:Received Date: Dec 01, 2023 / Accepted Date: Dec 30, 2023 / Published Date: Dec 30, 2023
Copyright: © 2024 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Vancomycin, a glycopeptide antibiotic renowned for its efficacy against gram-positive bacterial infections, has been
a mainstay in the treatment of serious infections, particularly those caused by methicillin-resistant Staphylococcus
aureus (MRSA). Vancomycin is primarily administered intravenously due to its negligible oral absorption. The drug
exhibits a large volume of distribution, predominantly in the extracellular fluid, with limited penetration through the
blood-brain barrier. Despite its significant role in combating infections, Vancomycin is not metabolized extensively
in the body. Dosing adjustments are crucial, particularly in patients with impaired renal function, to prevent drug accumulation and associated toxicity. Extended interval dosing strategies may be employed to optimize efficacy while minimizing nephrotoxic and ototoxic risks. Special populations, including pediatric and elderly patients, as well as those with obesity, may require individualized dosing approaches.
